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in the epidermis. In the steady state, 
the LC network is maintained through 
local proliferation of LCs themselves. 
Depending on the kind of inflamma-
tion induced in the skin, repopulation 
occurs by local proliferation of precur-
sor cells, e.g., in the case of contact 
sensitization or by monocytes recruited 
from the blood after UV treatment, as 
shown previously (Merad et al., 2008). 
CD103+ dermal langerin+ DCs are 
repopulated by circulating precursors 
not only in skin but also in lung, liver, 
kidney, and gut epithelium (Bogunovic 
et al., 2009) in a Flt-3 dependent and 
M-CSF-receptor-independent fashion, 
as opposed to epidermal LCs, where 
the inverse occurs.
Fréderic Geissmann and Laurent 
Chorro (London) demonstrated that in 
embryonic mice CD115+ CX3CR1+ LC 
precursors settle in the epidermis in a 
single wave of recruitment. They acquire 
all the typical markers—langerin, major 
histocompatibility complex (MHC) 
class II, CD11c—shortly after birth and 
then fill the epidermal compartment by 
high (“explosive”) proliferation within 
the first week after birth. Geissmann 
and Chorro proposed that it is the LCs 
themselves that proliferate in the steady 
state to maintain homeo stasis. They 
demonstrated that increased prolifera-
tion of LCs, but not the recruitment of 
a bone marrow–derived precursor, is 
induced in some types of skin inflam-
mation, such as atopic dermatitis. In 
these cases, a still unknown signal 
released by keratinocytes after stimu-
lation through the vitamin D receptor 
drives their proliferation.
The 11th International Workshop on 
Langerhans Cells,* organized by Niki 
Romani and Georg Stingl, took place 
in Funchal, Madeira, Portugal, where 
Paul Langerhans worked and died more 
than a hundred years ago. Langerhans 
(1847–1888) is buried at the British 
Cemetery, a place that was frequent-
ly visited by conference attendees 
(Figure 1). Robert Willan (1757–1812), 
the founder of modern, systematic der-
matology, is also at rest in this cemetery.
Georg Stingl (Vienna, Austria) 
opened the conference with a histor-
ical overview on Langerhans cell (LC) 
bio logy. It was intriguing to learn how 
several observations made many years 
ago (e.g., finding mitotic LCs) anti-
cipated recent data (e.g., division of LCs 
within the epidermis), particularly with 
regard to the ontogeny and homeostasis 
of LCs. In the two and a half days that 
followed, the conference concentrated 
on the ontogeny and functional role 
of LCs in the skin immune system and 
on finding ways to ultimately harness 
these properties for immunotherapy. 
Highlights are presented here.
Langerhans cell ontogeny  
and development
Miriam Merad (New York) summa-
rized current knowledge on LC ontog-
eny and function. She also presented 
new data on the repopulation of the 
skin by LCs and the recently discov-
ered dermal langerin+ dendritic cells 
(DCs) (Merad et al., 2008). LC precur-
sors populate murine epidermis during 
embryonic life, and they proliferate in 
situ to form the typical network of LCs 
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Florent Ginhoux (Singapore) comple-
mented Geissmann and Chorro’s data, 
showing that proliferating radioresistant 
CX3CR1+ LC precursors can be found 
in the epidermis of late mouse embryos. 
These radioresistant precursors develop 
into LCs within the first few days after 
birth; interestingly, they are derived 
from yolk sac macrophages. Kang Liu 
(New York) thoroughly dissected the 
sequence of progenitor stages (mye loid 
precursor, monocyte/DC precursor, 
common DC precursor, pre-DC) and 
the critical branching points for mono-
cytes, plasmacytoid DCs, and conven-
tional DCs in mouse bone marrow. The 
position of LCs within this developmen-
tal tree remains to be defined.
Junda Kel (Rotterdam, The Netherlands) 
reported that transforming growth 
factor-β (TGF-β) signaling is important 
to keep LCs in an immature state in 
the epidermis. When the TGF-β recep-
tor 1 is deleted under the control of 
the CD11c-promoter, LCs were pres-
ent in the epidermis of newborn mice, 
but their numbers decreased during 
development when the cells displayed 
a mature phenotype. This effect was 
specific for LCs (dermal (langerin+) 
DCs were not affected). As a result of 
the decreased number of LCs, con-
tact hypersensitivity reactions were 
impaired. These findings were under-
scored by Florian Sparber (Innsbruck, 
Austria), who presented a mouse model 
in which DCs lacked the p14 adap-
tor molecule for signal transduction 
involved in growth factor signaling. LC 
density in these mice was dramatically 
decreased, hinting at a malfunction of 
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the TGF-β receptor pathway. Likewise, 
Martin Zenke (Aachen, Germany) 
demonstrated that the transcription 
factor Id2, involved in TGF-β signal-
ing, is important for population of the 
skin with both LCs and dermal lan-
gerin+ DCs in steady state, but that Id2 
is not required for LC repopulation in 
inflammation.
Adelheid Elbe-Bürger (Vienna) report-
ed studies in human prenatal skin. She 
described in detail the development 
of the LC network in the epidermis. 
Similar to the mouse system, there is 
a high proliferation rate of CD45+ leu-
kocytes in the fetal/embryonic skin; 
the rate of proliferation decreases after 
birth. During the first to second trimes-
ter, markers on epidermal leukocytes 
are expressed in a stepwise order: first 
HLA-DR, then CD1c, followed by lan-
gerin and CD1a. Interestingly, this cor-
related with TGF-β expression in the 
epidermis. High expression of IL-10 in 
embryonic skin seems to keep the LCs 
in a functional blockade (Schuster et al., 
2009). Christopher Schuster (Vienna) 
supplemented these data by demon-
strating that precursors of dermal DCs 
are detectable at 9 weeks of embryonic 
life and express markers such as CD14, 
HLA-DR, and CD36.
In summary, the findings presented in 
the ontogeny session demonstrated that 
during embryonic life highly proliferative 
precursors settle in the epidermis and, 
upon birth, the dense network of LCs 
starts to form in both mouse and human 
skin. The proliferation rate is reduced 
after birth and during adult life. LCs 
themselves repopulate the epidermis in 
steady state and in some inflammatory 
settings. TGF-β and IL-10 seem to be 
important factors for keeping LCs in an 
immature stage in the epidermis in the 
steady state. The exact mechanisms that 
control LC homeostasis in adult skin 
remain to be established.
DC migration is tightly coupled  
with antigen uptake
Gwen Randolph (New York) described 
how DCs in the adipose tissue around 
lymph nodes acquire soluble anti-
gens that drain from the skin lym-
phatics for later presentation in the 
skin-draining lymph node. Ana-Maria 
Lennon-Duménil (Paris) demonstrated 
that the ability of DCs to sample anti-
gen is inversely correlated with their 
ability to migrate. Using microchan-
nel chambers, she showed that shortly 
after activation, bone marrow–derived 
DCs coexpress myosin II and the invari-
ant chain in the front portion of the 
cell, and they move slowly to be able 
to incorporate and process antigen. 
Upon further maturation, they trans-
locate myosin and the invariant chain 
to the rear of the cell and begin rapid 
migration to lymph nodes, where they 
meet T cells (Faure-Andre et al., 2008). 
It would be interesting to validate this 
mechanism in LCs. Along these lines, 
Ira Mellman (South San Francisco, CA) 
stressed that “phenotypically mature” 
DCs need not necessarily be “function-
ally mature” DCs. He pinpointed yet 
another specialization of DCs for effi-
cient presentation: unlike macropino-
cytosis, receptor-mediated endocytosis 
via clathrin-coated pits and vesicles 
does not stop upon maturation. This 
allows DCs to perform multiple rounds 
of processing and presentation.
A novel form of antigen uptake by 
LCs was presented by Akiharu Kubo 
(Tokyo). Upon activation achieved by 
mild tape stripping, the investigators 
observed that LCs extend dendrites into 
the stratum corneum and form tight 
junctions with surrounding keratino-
cytes. This could allow LCs to incor-
porate antigens or pathogens from the 
surface of the skin without compromis-
ing epidermal barrier function. Nancy 
Luckashenak (Munich) examined the 
importance of Cdc42 Rho GTPase in 
Figure 1. Conference attendees at the gravesite of paul Langerhans.
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DC migration. Upon depletion under 
the CD11c-promoter, LCs stop migrat-
ing to the lymph node and cannot 
exit the epidermis. As a consequence, 
transport of antigen such as FITC to the 
lymphatic tissue is greatly reduced. 
Together these findings indicate that 
migration and antigen incorporation 
are tightly coupled, ensuring that LCs/
DCs present antigens efficiently in lym-
phoid tissues.
LCs in infection
The role of LCs in skin infection is still 
largely unknown. However, several 
reports highlighted the fact that skin 
DCs can incorporate various patho-
gens and are involved in the clearance 
of pathogens. Teunis Geijtenbeek and 
colleagues (Amsterdam) observed that 
LCs derived from human epidermis 
are able to prevent transmission of HIV 
(Cunningham et al., 2008), herpes sim-
plex virus (HSV), hepatitis C virus, and 
measles virus after binding to langerin. 
This would endow LCs with a special 
(innate) function in neutralizing viruses, 
in contrast to other DCs (such as der-
mal DCs) that transmit HIV to T cells. 
Geijtenbeek further reported that in the 
case of inflammation or when doses 
of virus are too high, LCs are no lon-
ger able to eliminate them (de Jong et 
al., 2008). The picture is slightly dif-
ferent in the model of vaginal epithe-
lium as presented by Florian Hladik 
(Seattle, WA). Here, the main recep-
tors for HIV uptake are CD4 and CCR5. 
In vaginal LCs these receptors do not 
support productive fusion, but rather 
nonproductive endocytosis followed 
by transmission of infectious virions to 
T cells through infectious synapses. In 
vaginal mucosa langerin expression is 
low on LCs facing the lumen, indicat-
ing that this could explain why vaginal 
LCs might not be able to eliminate HIV 
through the langerin pathway.
Yonatan Ganor (Paris) observed that 
inner foreskin was highly permissive 
of HIV infection and that in this tissue 
virus was transmitted by LCs to T cells, 
whereas the outer foreskin is thicker 
and less permissive of HIV infection. 
Vassili Soumelis (Paris) showed that 
human papillomavirus (HPV)-infected 
skin lesions are devoid of LCs. He pre-
sented evidence supporting a role for 
thymic stromal lymphopoietin, which 
was expressed by HPV-infected kerati-
nocytes, in inducing emigration of LCs. 
M. de Jong (Amsterdam) reported that 
human LCs can transfer UV-inactivated 
measles virus to cocultured monocyte-
derived DCs, which in turn are readily 
able to cross-present viral antigen to 
CD8+ T cells. On the basis of these 
observations, she speculated that 
antigen transfer from LCs to other 
antigen-presenting cells may occur in 
the dermis.
Consistent with this, Bill Heath 
(Melbourne, Australia) noted that dur-
ing the second wave of HSV infection, 
which corresponds to a recrudescence 
phase involving the entire innervated 
dermatome, cutaneous CD103+ DCs 
(but no other migratory DCs from skin) 
and CD8+ lymph node–resident DCs 
present HSV antigen to CD8+ T cells. 
LCs play a minor direct role in antigen 
presentation, possibly because they are 
infected and then killed by this cytolytic 
virus. However, they may contribute to 
antigen transfer. In the primary wave of 
infection, only CD8+ DCs are capable 
of performing cross-presentation in the 
node, again indicating antigen transfer 
from infected skin DCs to lymph node 
resident DCs (Bedoui et al., 2009). 
Miriam Merad (New York) has observed 
that lung CD103+ DCs express high lev-
els of TLR3. In a mouse model of influ-
enza infection, lung DCs that coexpress 
langerin were shown to be mandatory 
for the induction of CD8+ T cell respons-
es because depletion of langerin+ cells 
prevented virus clearance, as presented 
by Hamida Hammad (Ghent, Belgium) 
(Geurtsvankessel et al., 2008). In this 
model, however, it was impossible to 
distinguish between CD103+ and CD8+ 
DCs because langerin is expressed on 
most lung CD103+ DCs and on a pro-
portion of lung-draining lymph node–
resident DC populations.
LCs might also be important in regu-
lating immune responses to nonviral 
pathogens. In a Leishmania infection 
model, the depletion of LCs enhanced 
T helper type 1 responses, resulting 
in smaller lesions after intradermal 
infection with physiological doses of 
parasites. Concomitantly, numbers of 
regulatory T cells were decreased, as 
demonstrated by Kordula Kautz-Neu 
(Mainz, Germany), suggesting a sup-
pressive role for LCs during Leishmania 
infection. In contrast, LCs might be less 
important in antibacterial immunity—
Marcel Teunissen (Amsterdam) showed 
that, in addition to a selective lack of 
Toll-like receptors essential for bacte-
rial recognition, human LCs take up, 
process, and present bacterial antigens 
poorly compared with dermal DCs. 
Dermal DCs also express more Fcγ 
receptors and more molecules associ-
ated with the MHC class II processing/
presentation pathway than do LCs. LCs’ 
poor responsiveness to bacteria might 
be an essential feature to maintain tol-
erance to the commensal bacterial flora 
on the skin.
In summary, LCs may play different 
roles depending on the agent and site 
of infection.
Depletion of LCs and what we learn  
from the new mouse models
Four years ago, three groups inde-
pendently developed mouse models 
in which LCs can be depleted either 
constitutively or conditionally. For this 
purpose, either the diphtheria toxin 
subunit A or the receptor for diphtheria 
toxin was expressed under the langerin 
promoter (Kaplan et al., 2008). These 
models were presented for the first time 
at the 9th International Workshop on 
Langerhans Cells in Madeira in 2005, 
and they revealed initially surprising 
differences in contact hypersensitivity 
responses. In the meantime, these mice 
were freely distributed, and many labs 
have used them to investigate the role 
of LCs in the induction of immunity 
and tolerance. Therefore, expectations 
were high for the presentations at the 
11th workshop.
Bernard Malissen (Marseille, France) 
started the discussion by subdividing 
skin DCs into five subsets: epidermal 
LCs, LCs in transit through the dermis, 
dermal langerin+ DCs, and two types 
of dermal langerin-negative DCs. He 
noted that CD103, which has been 
used as a marker to distinguish LCs and 
dermal langerin+ DCs, is not expressed 
on all of the latter cells. Therefore, 
caution is warranted when using it as 
a marker for separating skin DC sub-
sets in the lymph node. Björn Clausen 
(Rotterdam) presented data on a mouse 
Stoitzner et al.
11th International Workshop on Langerhans Cells
334 Journal of Investigative Dermatology (2010), Volume 130 
model in which β-catenin is stabilized 
specifically in DCs. As a consequence, 
the number of regulatory T cells was 
increased and contact hypersensitivity 
reactions were downregulated, provid-
ing in vivo evidence that this pathway 
promotes a tolerogenic DC function. 
In a mouse model lacking the IL-10 
receptor in DCs, contact hypersensitiv-
ity reactions were increased, indicat-
ing that IL-10 signaling in skin DCs is 
important to contain and regulate effec-
tor T-cell responses. In langerin-DTR 
mice, high doses of contact sensitizer 
are presented by both LCs and dermal 
DCs, but low amounts require LCs for 
the efficient induction of an immune 
response. Dermal langerin+ DCs play a 
minor role in this system.
This is in contrast to the langerin-
DTA mice studied by Dan Kaplan 
(Minneapolis, MN) that exhibit exag-
gerated contact hypersensitivity reac-
tions with both high and low doses of 
contact allergen in the absence of epi-
dermal LCs. Kaplan replicated these 
results in a newly developed abla-
tion model in which only epidermal 
LCs (but not dermal langerin+ DCs) 
are depleted upon administration of 
diphtheria toxin. This suggests that it is 
not the lifelong absence of LCs in the 
langerin-DTA mice that is responsible 
for their augmented contact hyper-
sensitivity. In the langerin-DTA mice, 
more antigen-specific effector T cells 
are present in skin and lymph nodes, 
and LC expression of MHC class II and 
IL-10 is important for the enhanced 
responses. Also, in Candida infection 
experiments, both LC-depletion models 
revealed increased responses to topi-
cal infection. Tetsuya Honda (Kyoto, 
Japan) devised a clever chimera model 
in which langerin-DTR mice could be 
depleted only of dermal langerin+ DCs 
and not of LCs. These mice exhibited 
no difference in contact hypersensitiv-
ity, although the degree of dermal DC 
chimerism has not been clearly estab-
lished in these mice. This model will be 
helpful for further investigation of the 
relative roles of LCs and dermal lan-
gerin+ DCs.
Discrepancies between the inducible 
and the constitutive ablation models were 
also evident in tumor models. Patrizia 
Stoitzner (Innsbruck) reported increased 
numbers of chemically induced tumors 
in depleted langerin-DTR mice in 
comparison with wild-type mice. This 
would indicate a role for langerin+ 
cells in tumor immuno surveillance. 
Interestingly, langerin-DTA mice were 
completely protected from tumors 
in the same tumor setting (Strid et al., 
2008). Using a murine atopic dermati-
tis model, Sandrine Dubrac (Innsbruck) 
found that LCs were required for the 
development of disease. After deple-
tion of LCs, Th2 responses and, as a 
consequence, disease severity, were 
markedly reduced.
The role of LCs in tolerance induc-
tion was directly addressed by Elena 
Shklovskaya (Sydney, Australia). In 
an elegant chimeric mouse model, in 
which MHC class II presentation was 
restricted to either LCs or dermal DCs, 
LCs induced tolerance and dermal DCs 
stimulated immunity after subcutaneous 
and topical immunization (Shklovskaya 
et al., 2008).
So, are we any further along? Yes. 
Some questions were indeed resolved; 
but discrepancies and seemingly con-
tradictory observations among the 
various models remain. One important 
lesson can be learned from these mod-
els: the role of LCs in the skin immune 
system is manifold, depending on the 
circumstances in the skin (steady state 
vs. inflammation), the pathogens, and 
the doses of antigens, among others. 
The notion (and the evidence) that LCs 
in vivo can act in a tolerogenic/down-
regulatory fashion has certainly been 
reinforced by the data presented in 
Funchal.
Skin DCs in pathology and  
potential new vaccination strategies
The closing session of the conference 
dealt mostly with human skin DCs in 
various pathologies and highlighted 
potential novel vaccination strategies.
Michelle Lowes (New York) further 
characterized the complex popula-
tions of skin DCs in diseased skin. 
Intriguingly, phenotypically mature-
appearing DCs in squamous cell car-
cinoma were functionally impaired, 
made tumor necrosis factor-α and 
inducible nitric oxide synthase, and 
may contribute to the ability of the 
tumor to evade immunosurveillance 
(Bluth et al., 2009). For the past 2 years, 
we have been searching for a human 
counterpart of mouse dermal langerin+ 
DCs. At this meeting, Matthew Collin 
(Newcastle, UK) reported a very likely 
candidate, namely, a langerin+ EpCAM− 
DC in human dermis. CD103 seems 
to be an unreliable marker for these 
cells. The dermal langerin+ DC equiva-
lent was found even in human bone 
marrow transplant patients (Haniffa et 
al., 2009), emphasizing the value of 
patient-oriented research by excellent 
physician–scientists. As in the mouse, 
this cell type is of donor origin.
Hideki Ueno (Dallas, TX) presented 
data on a functional dichotomy between 
human LCs and dermal DCs. LCs are 
superior in the induction of cytotoxic 
T cells but can also stimulate strong 
Th2 responses. Dermal DCs produce 
IL-12, which induces follicular T helper 
cells that in turn regulate antibody 
secretion by B cells, making them per-
fect stimulators of humoral responses 
(Banchereau et al., 2009). Carl Allen 
(Houston, TX) discussed the origin of 
the LC histiocytosis (LCH), which con-
sists of an accumulation of langerin+ 
cells in tissue and occurs mostly in chil-
dren. It is still not certain whether LCH 
is a neoplastic or an inflammatory dis-
ease. Expression-profile analysis using 
microarray suggested that LCH cells are 
more closely related to bone marrow 
myeloid cells than to LCs or dermal lan-
gerin+ DCs that are present in normal 
skin. Therefore, Allen proposed LCH as 
a “myeloid proliferative disorder.”
The novel therapeutic approach 
of targeting antigen to DCs via lectin 
receptors was discussed in several talks. 
Irina Caminschi (Melbourne) presented 
Clec9A and Clec12A as potential candi-
dates that specifically target CD8+ DCs 
and plasmacytoid DCs. The require-
ment for adjuvants differs between the 
two delivery antibodies; however, both 
are efficient in the stimulation of CD4+ 
and CD8+ T-cell responses. Juliana 
Idoyaga (New York) discovered that all 
CD8+ DCs in the spleen of BALB/c mice 
(i.e., spleen-resident DCs) coexpress 
langerin, making them potential targets 
for langerin antibody–conjugated 
antigens. Indeed, intravenously injected 
anti-langerin-antigen conjugates were 
able to stimulate potent CD4+ and CD8+ 
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T-cell responses in vivo. Regarding 
CD205-conjugated antigens, the obser-
vation by Ira Mellman (San Francisco, 
CA) that even mature DCs can take up 
and present such conjugates (because 
receptor-mediated endocytosis is opera-
tive in this case) may be of great value for 
developing immunotherapies. Vincent 
Flacher (Innsbruck) demonstrated that 
topical imiquimod (Aldara cream) 
can induce migration of skin DCs and 
increase the number of CD205-targeted 
cells in the lymph nodes after intrader-
mal immunization. Interestingly, most 
targeted cells were langerin+ DCs. Anti-
CD205-antigen conjugates induced 
potent cytotoxic responses, emphasizing 
their future therapeutic potential.
Summary
The presence of 140 scientists from 
all over the world, working on various 
aspects of LC and DC biology, made 
this meeting exciting and productive. 
The functions of LCs in the skin immune 
system in vivo seem to be manifold. 
Clearly, LCs are involved in immune 
responses against pathogens and skin 
tumors and perform a regulatory role by 
downmodulating immune responses—
or even promoting disease progression. 
These characteristics make them attrac-
tive targets for therapeutic interventions 
through the skin. Nevertheless, many 
questions must be answered before LCs 
and other skin DCs can be harnessed 
for immunotherapy on a large scale. 
With new mouse models, new sort-
ing strategies for the various skin DC 
subsets, and—most importantly—more 
studies with human cells, human dis-
eases, and patients, we will be able to 
illuminate these remaining mysteries. 
This will ultimately be of benefit for 
medicine and, as a consequence, for 
industry.
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* The 11th International Workshop on Langerhans 
Cells was held at the CS Madeira Atlantic Resort 
and Sea Spa in Funchal, Portugal, 3–6 September 
2009.
The 12th International Workshop on Langerhans 
Cells will take place in the fall of 2011 in Bethes-
da, Maryland, USA (http://www.lc2011.org).
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